Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

  • ID: 3843311
  • Report
  • Region: Asia
  • 176 pages
  • GBI Research
1 of 6
Newer Therapies Will Steer Type 2 Diabetes Market in South-East Asia to $2.7 Billion by 2022

FEATURED COMPANIES

  • Astellas
  • Boehringer Ingelheim
  • Dong-A ST
  • GlaxoSmithKline
  • JW Pharmaceutical
  • Merck
  • MORE
Diabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both of these (ADA, 2014b). This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels.

The market for Type 2 Diabetes Mellitus (T2DM) is expected to grow from USD1.7 Billion in 2015 to USD2.7 Billion in 2022, at a Compound Annual Growth Rate (CAGR) of 7.1%. This growth will be driven by the rapidly expanding prevalence population, due to increasingly aging populations and sedentary lifestyles, as well as increases in the diagnosis and treatment rates, due to rising disease awareness among the public.

T2DM market contains a wide range of drugs that are used to treat patients at different points in the treatment algorithm. The drug therapies are broadly classified into insulin therapies and non-insulin agents. The patient share for these categories varies from country to country.

The pipeline for T2DM is very large, with 516 active products at a disclosed stage of development. The number and high level of diversity of these products suggests that there is a strong potential for unmet needs to be addressed in the coming years. In particular, the late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes, in comparison to currently marketed products.

As per Aswini Nath, “Unmet needs relating to patient convenience and ease of use will be addressed significantly over the forecast period. Higher levels of innovation are apparent in the early-stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy in the long term”.

The report “Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth” provides an introduction to Type 2 Diabetes Mellitus (T2DM), including disease introduction, epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment options, treatment segments, and co-morbidities and complications.

In depth, it provides the following:
  • Provides an overview of the T2DM marketed products landscape, including product profiles of key marketed products and heat maps that compare the safety and efficacy parameters of the various drugs.
  • Analyses of T2DM pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target.
  • Provides detailed analysis of recent clinical trials in T2DM by enrollment, duration and failure rate.
  • Provides forecasts for the T2DM market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015-2022 period. The eight South-East Asia markets are covered, and data is presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for T2DM in South-East Asia markets.
  • Provides detailed analysis of major deals that have taken place in the global T2DM market in recent years.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Astellas
  • Boehringer Ingelheim
  • Dong-A ST
  • GlaxoSmithKline
  • JW Pharmaceutical
  • Merck
  • MORE
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.6 Classification
2.7 Prognosis
2.8 Treatment Options
2.8.1 Treatment Algorithm
2.8.2 Non-insulin T2DM Therapies
2.8.3 Insulin T2DM Therapies
2.9 Treatment Segments
2.9.1 Non-insulin therapies
2.9.2 Insulin Therapies
2.10 Co-morbidities and Complications
3 Marketed Products
3.1 Overview
3.2 Biguanides
3.2.1 Metformin
3.3 Sulfonylureas
3.4 Thiazolidinediones
3.4.1 Pioglitazone
3.4.2 Duvie (lobeglitazone) - Chong Kun Dang
3.5 GLP-1 Receptor Agonists
3.5.1 Byetta (exenatide) - Eli Lilly
3.5.2 Bydureon (exenatide) - AstraZeneca
3.5.3 Victoza (liraglutide) - Novo Nordisk
3.5.4 Lyxumia (lixisenatide) - Sanofi
3.5.5 Tanzeum (albiglutide) - GlaxoSmithKline
3.6 DPP-4 Inhibitors
3.6.1 Januvia (sitagliptin) - Merck
3.6.2 Galvus (vildagliptin) - Novartis
3.6.3 Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca
3.6.4 Trajenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca
3.6.5 Zemiglo (gemigliptin) - LG Life Sciences
3.6.6 Suganon (evogliptin) - Dong-A ST
3.6.7 Gadret (anagliptin) - JW Pharmaceutical
3.6.8 Nesina (alogliptin) - Takeda
3.6.9 Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma
3.7 SGLT-2 Inhibitors
3.7.1 Forxiga (dapagliflozin) - AstraZeneca
3.7.2 Invokana (canagliflozin) - Janssen
3.7.3 Jardiance (empagliflozin) - Boehringer Ingelheim
3.7.4 Suglat (ipragliflozin) - Astellas
3.8 Insulin Therapies
3.8.1 Lantus (insulin glargine) - Sanofi
3.8.2 Levemir (insulin detemir) - Novo Nordisk
3.8.3 Tresiba (insulin degludec) - Novo Nordisk
3.8.4 Toujeo (insulin glargine) - Sanofi
3.9 Comparative Efficacy and Safety of Marketed Products
4 Pipeline
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk
4.4.2 Trulicity (dulaglutide)
4.4.3 Ertugliflozin - Pfizer
4.4.4 Bexagliflozin - Theracos
4.4.5 Omarigliptin - Merck
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitive Framework
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Stage of Development and Molecule Type
5.3.2 Trial Duration by Stage of Development and Molecular Target
5.4 Summary of Clinical Trial Metrics
6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 South-East Asia Markets
6.3 South Korea
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 Singapore
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Taiwan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Malaysia
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Philippines
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
6.8 Thailand
6.8.1 Treatment Usage Patterns
6.8.2 Annual Cost of Therapy
6.8.3 Market Size
6.9 Vietnam
6.9.1 Treatment Usage Patterns
6.9.2 Annual Cost of Therapy
6.9.3 Market Size
6.10 Indonesia
6.10.1 Treatment Usage Patterns
6.10.2 Annual Cost of Therapy
6.10.3 Market Size
7 Market Dynamics, (Drivers and Barriers)
7.1 Drivers
7.1.1 Aging Population, Increasing Obesity and Growing Economy
7.1.2 Increasing Awareness of T2DM
7.1.3 Continued Uptake of Recently Approved Drug Classes
7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm
7.1.5 Enhanced Usage of Combination Therapies
7.2 Barriers
7.2.1 Non-pharmacological First-line Treatment
7.2.2 Widespread Usage of Generic Drugs
7.2.3 Poor Adherence to Treatment Regimens
7.2.4 Generic Erosion Resulting from Patent Expirations
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-Development Deals
9 Appendix
9.1 All Pipeline Drugs by Phase of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Market Forecasts to 2022
9.2.1 South-East Asia
9.2.2 South Korea
9.2.3 Singapore
9.2.4 Taiwan
9.2.5 Malaysia
9.2.6 Philippines
9.2.7 Thailand
9.2.8 Vietnam
9.2.9 Indonesia
9.3 References
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Pipeline Analysis
9.5.6 Forecasting Model
9.5.7 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy
Table 2: T2DM Therapeutics, Global, All Pipeline Products, Discovery Stage, March 2016
Table 3: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Stage, March 2016
Table 4: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Stage, March 2016
Table 5: T2DM Therapeutics, Global, All Pipeline Products, Phase I, March 2016
Table 6: T2DM Therapeutics, Global, All Pipeline Products, Phase II, March 2016
Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase III, March 2016
Table 8: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration Stage, March 2016
Table 9: T2DM Therapeutics Market, South-East Asia, Market Forecast, 2015-2022
Table 10: T2DM Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 11: T2DM Therapeutics Market, Singapore, Market Forecast, 2015-2022
Table 12: T2DM Therapeutics Market, Taiwan, Market Forecast, 2015-2022
Table 13: T2DM Therapeutics Market, Malaysia, Market Forecast, 2015-2022
Table 14: T2DM Therapeutics Market, Philippines, Market Forecast, 2015-2022
Table 15: T2DM Therapeutics Market, Thailand, Market Forecast, 2015-2022
Table 16: T2DM Therapeutics Market, Vietnam, Market Forecast, 2015-2022
Table 17: T2DM Therapeutics Market, Indonesia, Market Forecast, 2015-2022

1.2 List of Figures
Figure 1: T2DM Therapeutics Market, South-East Asia, Heat Map for Marketed Products, 2016
Figure 2: T2DM Therapeutics Market, South-East Asia, Heat Map for Marketed Products, 2016 (continued)
Figure 3: T2DM Therapeutics Market, Global, Pipeline, 2016
Figure 4: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 5: T2DM Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 6: T2DM Therapeutics Market, South-East Asia, NN-9535 Forecast ($m), 2018-2022
Figure 7: T2DM Therapeutics Market, South-East Asia, OG-217SC Forecast ($m), 2020-2022
Figure 8: T2DM Therapeutics Market, South-East Asia, Trulicity Products Forecast ($m), 2016-2022
Figure 9: T2DM Therapeutics Market, South-East Asia, Ertugliflozin Products Forecast ($m), 2018-2022
Figure 10: T2DM Therapeutics Market, South-East Asia, Bexagliflozin Products Forecast ($m), 2020-2022
Figure 11: T2DM Therapeutics Market, South-East Asia, Omarigliptin Products Forecast ($m), 2017-2022
Figure 12: T2DM Market, South-East Asia, Heat Map for Pipeline Products, March 2016
Figure 13: T2DM Therapeutics Market, South-East Asia, Competitor Matrix for Marketed and Pipeline Products, March 2016
Figure 14: T2DM Therapeutics, Global, Clinical Trial Attrition Rates (%), 2006-March 2016
Figure 15: T2DM Therapeutics, Global, Clinical Trial Attrition Rates by Molecule Type (%), 2006-March 2016
Figure 16: T2DM Therapeutics, Global, Clinical Trial Attrition Rates by Molecular Target (%), 2006-March 2016
Figure 17: T2DM Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-March 2016
Figure 18: T2DM Therapeutics, Global, Clinical Trial Size per Product Molecular Target (participants), 2006-March 2016
Figure 19: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-March 2016
Figure 20: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-March 2016
Figure 21: T2DM Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-March 2016
Figure 22: T2DM Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-March 2016
Figure 23: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecule Type, 2006-March 2016
Figure 24: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Target, 2006-March 2016
Figure 25: T2DM Therapeutics Market, South-East Asia, Treatment Usage Patterns (million), 2015-2022
Figure 26: T2DM Therapeutics Market, South-East Asia, Market Size ($bn), 2015-2022
Figure 27: T2DM Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2015-2022
Figure 28: T2DM Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 29: T2DM Therapeutics Market, South Korea, Market Size ($m), 2015-2022
Figure 30: T2DM Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2015-2022
Figure 31: T2DM Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2015-2022
Figure 32: T2DM Therapeutics Market, Singapore, Market Size ($m), 2015-2022
Figure 33: T2DM Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2015-2022
Figure 34: T2DM Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2015-2022
Figure 35: T2DM Therapeutics Market, Taiwan, Market Size ($m), 2015-2022
Figure 36: T2DM Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2015-2022
Figure 37: T2DM Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2015-2022
Figure 38: T2DM Therapeutics Market, Malaysia, Market Size ($m), 2015-2022
Figure 39: T2DM Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2015-2022
Figure 40: T2DM Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2015-2022
Figure 41: T2DM Therapeutics Market, Philippines, Market Size ($m), 2015-2022
Figure 42: T2DM Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2015-2022
Figure 43: T2DM Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2015-2022
Figure 44: T2DM Therapeutics Market, Thailand, Market Size ($m), 2015-2022
Figure 45: T2DM Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2015-2022
Figure 46: T2DM Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2015-2022
Figure 47: T2DM Therapeutics Market, Vietnam, Market Size ($m), 2015-2022
Figure 48: T2DM Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2015-2022
Figure 49: T2DM Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2015-2022
Figure 50: T2DM Therapeutics Market, Indonesia, Market Size ($m), 2015-2022
Figure 51: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value, 2006-March 2016
Figure 52: T2DM Therapeutics Market, Global, Licensing Deals by Region, 2006-March 2016
Figure 53: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-March 2016
Figure 54: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-March 2016
Figure 55: T2DM Therapeutics Market, Global, Licensing Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-March 2016
Figure 56: T2DM Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-March 2016
Figure 57: T2DM Therapeutics Market, Global, Co-development Deals by Value ($m), 2006-March 2016
Figure 58: T2DM Therapeutics Market, Global, Co-Development Deals by Region, 2006-March 2016
Figure 59: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-March 2016
Figure 60: T2DM Therapeutics Market, Global, Co-development Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-March 2016
Figure 61: T2DM Therapeutics Market, Global, Co-development Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-March 2016
Figure 62: T2DM Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-March 2016 136
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Astellas
  • Boehringer Ingelheim
  • Dong-A ST
  • GlaxoSmithKline
  • JW Pharmaceutical
  • Merck
  • MORE
Ours latest report* states that as well as the rapidly expanding prevalence population in South-East Asia, market growth will be driven by the increased uptake of recently approved and emerging branded T2DM therapeutics, in favor of lower-cost generic products.

One of the publishers analysts states that: “Unmet needs relating to patient convenience and ease of use will be addressed significantly over the forecast period. Higher levels of innovation are apparent in the early-stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy in the long term.

“In terms of recently approved therapeutics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors have already achieved strong market uptake and are all expected to increase their market shares over the forecast period. In comparison with many previously marketed therapies, these new products provide improved weight control and lowered hypoglycemia risk.”

In terms of late-stage pipeline products with the potential to change the treatment paradigm, six candidates stand out as offering superior safety, efficacy, and patient compliance. These are Novo Nordisk’s NN-9535 (semaglutide subcutaneous formulation) and OG-217SC (semaglutide oral formulation) and Eli Lilly’s Trulicity (dulaglutide), which are GLP-1 receptor agonists; Merck’s ertugliflozin and Theracos's bexagliflozin, which are SGLT-2 inhibitors; and Merck’s omarigliptin, which is a DPP-4 inhibitor.
Note: Product cover images may vary from those shown
5 of 6
- Astellas
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb/AstraZeneca
- Chong Kun Dang
- Dong-A ST
- Eli Lilly
- GlaxoSmithKline
- JW Pharmaceutical
- Janssen
- LG Life Sciences
- Merck
- Mitsubishi Tanabe Pharma
- Novartis
- Novo Nordisk
- Sanofi
- Takeda
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll